Toggle Main Menu Toggle Search

Open Access padlockePrints

Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)

Lookup NU author(s): Professor Caroline Relton

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.


Publication metadata

Author(s): Zuo H, Ueland PM, Midttun O, Tell GS, Fanidi A, Zheng W, Shu X, Xiang Y, Wu J, Prentice R, Pettinger M, Thomson CA, Giles GG, Hodge A, Cai Q, Blot WJ, Johansson M, Hultdin J, Grankvist K, Stevens VL, McCullough ML, Weinstein SJ, Albanes D, Ziegler RG, Freedman ND, Caporaso NE, Langhammer A, Hveem K, Naess M, Buring JE, Lee I, Gaziano JM, Severi G, Zhang X, Stampfer MJ, Han J, Zeleniuch-Jacquotte A, Marchand LL, Yuan J, Wang R, Koh W, Gao Y, Ericson U, Visvanathan K, Jones MR, Relton C, Brennan P, Johansson M, Ulvik A

Publication type: Article

Publication status: Published

Journal: Annals of Oncology

Year: 2019

Volume: 30

Issue: 3

Pages: 478-485

Online publication date: 30/01/2019

Acceptance date: 02/04/2018

ISSN (print): 0923-7534

ISSN (electronic): 1569-8041

Publisher: Oxford University Press

URL: https://doi.org/10.1093/annonc/mdz002

DOI: 10.1093/annonc/mdz002

PubMed id: 30698666


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share